ArticleChina CDC weekly2023

Immunogenicity and Safety of Homologous Booster Doses of CoronaVac COVID-19 Vaccine in Elderly Individuals Aged 60 Years and Older: A Dosing Interval Study - Yunnan Province, China, 2021-2022.

Haitao Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.